AR089853A1 - Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso - Google Patents
Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, usoInfo
- Publication number
- AR089853A1 AR089853A1 ARP130100282A ARP130100282A AR089853A1 AR 089853 A1 AR089853 A1 AR 089853A1 AR P130100282 A ARP130100282 A AR P130100282A AR P130100282 A ARP130100282 A AR P130100282A AR 089853 A1 AR089853 A1 AR 089853A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- independently
- membered
- alkoxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Reivindicación 1: Una combinación caracterizada porque comprende un compuesto de fórmula (1) o una sal del mismo farmacéuticamente aceptable, en la que: cada uno de R¹ y R² es independientemente hidrógeno, alquilo C₁₋₇ o carbociclo C₃₋₁₀, con la condición de que R¹ y R² no sean los dos hidrógeno; R³ es un anillo de heteroarilo de 5 - 11 miembros que contiene de uno a tres heteroátomos seleccionados entre nitrógeno, oxígeno y azufre, donde el anillo de heteroarilo está opcionalmente sustituido independientemente con uno a tres grupos seleccionados entre alquilo C₁₋₅ opcionalmente sustituido con uno a tres átomos de halógeno, alcoxi C₁₋₅, hidroxi C₁₋₃, halógeno, hidroxi, -O-bencilo, oxo, ciano, amino, -NH-carbociclo C₃₋₆, alquilamino C₁₋₆ y dialquilamino C₁₋₃; R⁴ es hidrógeno, alquilo C₁₋₃, halógeno o nitrilo; R⁵ es alquilo C₁₋₆, carbociclo C₃₋₁₀, heterociclo de 3 - 11 miembros, arilo, heteroarilo de 5 - 11 miembros, -C(O)-R⁶, hidroxi o -NR⁷R⁸, donde cada R⁵ está opcionalmente sustituido independientemente con uno a tres grupos seleccionados entre R⁹, R¹⁰ y R¹¹; R⁶ es heterociclo C₃₋₈ o -NH-heterociclo de 5 - 6 miembros, cada uno opcionalmente sustituido independientemente con uno a tres grupos seleccionados entre R⁹, R¹⁰ y R¹¹; cada uno de R⁷ y R⁸ es independientemente hidrógeno, heterociclo de 5 - 6 miembros opcionalmente sustituido con alquilo C₁₋₆, carbociclo C₃₋₁₀ opcionalmente sustituido con hidroxi o alquilo C₁₋₆; R⁹, R¹⁰ y R¹¹ se seleccionan independientemente entre (a) -H, (b) -OH, (c) halógeno, (d) -CN, (e) -CF₃, (f) alquilo C₁₋₆ opcionalmente sustituido con uno a tres -OH, -N(R¹²)(R¹³), heterociclo de 3 - 6 miembros, alcoxi C₁₋₆, alcoxi C₁₋₆-O-alquilo C₁₋₆, -CO₂R¹², -C(O)N(R¹²)(R¹³) o -S(O)ₙ-alquilo C₁₋₆, (g) alcoxi C₁₋₆, (h) -N(R¹²)(R¹³), (i) -S(O)ₙ-alquilo C₁₋₆, (j) -CO₂R¹², (k) -C(O)N(R¹²)(R¹³), (l) -S(O)₂N(R¹²)(R¹³), (m) un grupo heterocíclico de 3 - 10 miembros opcionalmente sustituido con uno a tres grupos alquilo C₁₋₆, (n) oxo, (o) -C(O)-alquilo C₁₋₃; cada uno de R¹² y R¹³ se selecciona independientemente entre -H, -alquilo C₁₋₆, C₍O₎ₐₗqᵘⁱₗₒ C₁₋₆, y un grupo heterocíclico de 3 - 6 miembros, cada uno de los cuales está opcionalmente sustituido independientemente con uno a tres grupos alquilo C₁₋₆, -OH, alcoxi C₁₋₆, -C(O)N(R¹⁴)(R¹⁵), -S(O)ₙ-alquilo C₁₋₆, CN, un grupo heterocíclico de 3 - 6 miembros, -O-alquilo C₁₋₆, CF₃, o; R¹² y R¹³ tomados junto con el anillo de nitrógeno al que están unidos forman un anillo de heterociclilo opcionalmente sustituido con uno a tres -OH, CN, -O-alquilo C₁₋₆ u oxo; cada uno de R¹⁴ y R¹⁵ se selecciona independientemente entre -H y alquilo C₁₋₆; n es 0, 1 ó 2; y un agente farmacéuticamente activo adicional para uso en un método para tratar una enfermedad cardiovascular. Reivindicación 16: La combinación según una cualquiera de las reivindicaciones 1 ó 13, caracterizada porque además comprende más de un agente farmacéuticamente activo adicional seleccionado de un grupo que consiste en estatinas, inhibidores de HMG-CoA reductasa, inhibidores o antagonistas de la proteína de transferencia de éster de colesterol (CETP), fibratos, derivados de niacina, inhibidores de Lp-PLA2, antiplaquetarios y anticoagulantes.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261593638P | 2012-02-01 | 2012-02-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR089853A1 true AR089853A1 (es) | 2014-09-24 |
Family
ID=47631435
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130100282A AR089853A1 (es) | 2012-02-01 | 2013-01-30 | Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso |
Country Status (7)
Country | Link |
---|---|
US (1) | US9248187B2 (es) |
EP (1) | EP2809321B1 (es) |
JP (1) | JP6069771B2 (es) |
AR (1) | AR089853A1 (es) |
TW (1) | TW201343641A (es) |
UY (1) | UY34604A (es) |
WO (1) | WO2013113799A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
CA2897420C (en) | 2013-03-27 | 2020-10-27 | F. Hoffmann-La Roche Ag | Genetic markers for predicting responsiveness to therapy |
ES2825675T3 (es) | 2014-07-30 | 2021-05-17 | Hoffmann La Roche | Marcadores genéticos para predecir la reactividad al tratamiento con un agente que aumenta las HDL o que imita las HDL |
US11679146B2 (en) | 2018-06-05 | 2023-06-20 | Anji Pharmaceuticals Inc. | Compositions and methods for treating pancreatitis |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL147976A0 (en) | 1999-08-06 | 2002-09-12 | Janssen Pharmaceutica Nv | Interleukin-5 inhibiting 6-azauracil derivatives |
US7319108B2 (en) | 2004-01-25 | 2008-01-15 | Sanofi-Aventis Deutschland Gmbh | Aryl-substituted heterocycles, process for their preparation and their use as medicaments |
EP1814877B1 (en) | 2004-10-18 | 2009-03-11 | Merck & Co., Inc. | Diphenyl substituted alkanes as flap inhibitors |
US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
US8399666B2 (en) | 2005-11-04 | 2013-03-19 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
GB2431927B (en) * | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
AU2007238878A1 (en) | 2006-04-11 | 2007-10-25 | Merck Sharp & Dohme Corp. | Diaryl substituted alkanes |
EP2452683A3 (en) | 2006-06-26 | 2012-08-22 | Amgen Inc. | Methods for treating atherosclerosis |
CA2666686A1 (en) * | 2006-09-01 | 2008-03-13 | Merck & Co., Inc. | Inhibitors of 5-lipoxygenase activating protein (flap) |
WO2008128335A1 (en) | 2007-04-20 | 2008-10-30 | Merck Frosst Canada Ltd. | Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
EP2170065A4 (en) | 2007-06-20 | 2011-11-23 | Merck Sharp & Dohme | DIPHENYL SUBSTITUTED ALKANES |
JP2011500563A (ja) | 2007-10-10 | 2011-01-06 | メルク・シャープ・エンド・ドーム・コーポレイション | ジフェニル置換されたシクロアルカン |
CN102271682B (zh) | 2008-10-31 | 2015-12-16 | 默沙东公司 | 用于治疗疼痛的p2x3受体拮抗剂 |
WO2010089686A1 (en) | 2009-02-04 | 2010-08-12 | Pfizer Inc. | 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one derivatives |
AU2011252974A1 (en) | 2010-05-12 | 2012-12-13 | Vanderbilt University | Heterocyclic sulfone mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
MX2013001872A (es) | 2010-08-16 | 2013-09-02 | Boehringer Ingelheim Int | Inhibidores de oxadiazol de la produccion de leucotrieno. |
US8580829B2 (en) | 2010-08-26 | 2013-11-12 | Boehringer Ingelheim International Gmbh | Oxadiazole inhibitors of leukotriene production |
IN2013DN02555A (es) | 2010-09-23 | 2015-08-07 | Boehringer Ingelheim Int | |
WO2012040137A1 (en) * | 2010-09-23 | 2012-03-29 | Boehringer Ingelheim International Gmbh | Oxadiazole inhibitors of leukotriene production |
-
2013
- 2013-01-30 AR ARP130100282A patent/AR089853A1/es unknown
- 2013-01-31 EP EP13702219.0A patent/EP2809321B1/en active Active
- 2013-01-31 US US13/755,351 patent/US9248187B2/en active Active
- 2013-01-31 TW TW102103835A patent/TW201343641A/zh unknown
- 2013-01-31 JP JP2014555197A patent/JP6069771B2/ja active Active
- 2013-01-31 WO PCT/EP2013/051871 patent/WO2013113799A1/en active Application Filing
- 2013-01-31 UY UY0001034604A patent/UY34604A/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP2809321B1 (en) | 2016-11-09 |
UY34604A (es) | 2013-07-31 |
US9248187B2 (en) | 2016-02-02 |
JP6069771B2 (ja) | 2017-02-01 |
WO2013113799A1 (en) | 2013-08-08 |
JP2015505550A (ja) | 2015-02-23 |
EP2809321A1 (en) | 2014-12-10 |
TW201343641A (zh) | 2013-11-01 |
US20130195879A1 (en) | 2013-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR092742A1 (es) | Piridinonas antifibroticas | |
AR088760A1 (es) | Derivados de pirrolopirimidina y purina | |
AR123089A2 (es) | Compuesto de piridinona | |
AR064561A1 (es) | Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina. | |
AR112533A2 (es) | Compuestos de tetraciclina sustituidos con flúor en c7 | |
AR103969A1 (es) | Inmunomoduladores | |
AR100418A1 (es) | Compuestos y composiciones para inducir condrogénesis | |
AR110153A1 (es) | ÁCIDOS PROPIÓNICOS 3-SUSTITUIDOS COMO INHIBIDORES DE LA INTEGRINA aV | |
AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
EA201691428A1 (ru) | Бициклические гетероциклические производные в качестве ингибиторов irak4 | |
AR091519A1 (es) | Inhibidores pirrolopirazona de tanquirasa | |
AR087841A1 (es) | Derivados de tetrahidrotriazolopirimidina | |
AR078504A1 (es) | Compuestos eficaces como inhibidores de la xantina-oxidasa, metodo para la preparacion de los mismos y composicion farmaceutica que los contiene | |
AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
AR070221A1 (es) | Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas. | |
SV2011004077A (es) | Derivados aminobutiricos sustituidos como inhibidores de neprilisina | |
CO6341631A2 (es) | Derivados de 1,2,4 - oxadiazol y su uso terapéutico | |
AR063096A1 (es) | Pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina | |
AR088226A1 (es) | Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas | |
AR094346A1 (es) | Derivados de azaindol como inhibidores de las proteína quinasas | |
AR097571A1 (es) | Compuestos espirocíclicos como inhibidores de la triptofano hidroxilasa | |
AR082696A1 (es) | Derivados heterociclicos nitrogenados de 1,2,4-oxadiazol, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades cardiovasculares e inflamatorias, entre otras | |
ECSP099269A (es) | Compuestos de fenilurea como inhibidores de epóxido hidrolasa soluble | |
AR093036A1 (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
AR093077A1 (es) | ANTAGONISTAS DE mGlu2/3 PARA EL TRATAMIENTO DE LOS TRASTORNOS AUTISTAS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |